-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Objective: To study the changes of metabolites in the plasma of patients with systemic lupus erythematosus (SLE) to identify new biomarkers and provide clues for the pathogenesis of S.
Methods: SLE patients (n = 41, discovery cohort and n = 37, replication cohort), healthy controls (HCs, n = 30 and n = 29), rheumatoid arthritis patients (n = 19, disease controls) were recruit.
Metabolic profiles of plasma samples were analyzed by liquid chromatography-time-of-flight mass spectrometry (LC-TOFMS) and capillary electrophoresis-time-of-flight mass spectrometry
(CE-TOFMS.
Transcriptomic data of 18 immune cell subsets were analyzed using RNA-S.
The importance of histidine (His) in plasmablast differentiation was investigated using mouse splenic B cel.
Results: Specific amino acid combinations including His could effectively differentiate SLE patients from HCs
Random forests and partial least squares discriminant analysis (PLS-DA) identified His as an effective classifier for SLE patients
Decreased His plasma levels were associated with accumulation of damage, independent of prednisolone dose and type I interferon (IFN) profi.
Efficiently distinguishing SLE patients from HCs His is an efficient classifier for SLE patients
Conclusions: Plasma His level is a potential biomarker in SLE patients and is associated with injury accumulation
Plasma His level is a potential biomarker in SLE patients and is associated with injury accumulation Plasma His level is a potential biomarker in SLE patients and is associated with injury accumulation Pathogenic metabolites SLE pathogenesis
Source: Iwasaki Y, Takeshima Y, Nakano M, et .
Source: Iwasaki Y, Takeshima Y, Nakano M, et .
Combined plasma metabolomic and transcriptomic analysis identify histidine as a biomarker and potential contributor in SLE pathogenesis [published online ahead of print, 2022 Jun 1
Rheumatology (Oxfor.
2022; keac33 doi:11093/rheumatology/keac338 leave a message here
